- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
First Clinical Trial With Induced Pluripotent Stem Cells Grows Closer
26 June 2013 12:05 pm
A Japan Ministry of Health, Labour and Welfare panel has accepted a plan to carry out what would be the world's first clinical trials involving induced pluripotent stem (iPS) cells. The acceptance paves the way for an official green light from the ministry, which could come in early July.
Researchers at the RIKEN Center for Developmental Biology in Kobe plan to generate replacement retinal pigment epithelial cells from iPS cells generated from patients suffering age-related macular degeneration. The research has been under way for several years and was widely reported at conferences.
Approval for clinical trials was expected to be routine. However, the health ministry panel cited safety concerns in putting off a decision in late May. Japanese media reported that the panel met again today and accepted additional data submitted by RIKEN. Formal approval will be up to the ministry. RIKEN could start recruiting patients sometime this year.